JBPHF (Jacobio Pharmaceuticals Group Co) Long-Term Debt: $12.65 Mil (As of Dec. 2025)


JBPHF Jacobio Pharmaceuticals Group Co Ltd JBPHF
54 GF Score
Price $0.87
GF Value $0.34
! 6 Warning Signs
View Full Analysis

What is Jacobio Pharmaceuticals Group Co Long-Term Debt?

Jacobio Pharmaceuticals Group Co JBPHF +4.52% 54 Long-Term Debt is $12.65 Mil as of Dec. 2025. GuruFocus rates JBPHF with a GF Score™ of 54/100 and a GF Value™ of $0.34. The stock has 6 warning signs investors should review.

Jacobio Pharmaceuticals Group Co's Long-Term Debt for the quarter that ended in Dec. 2025 was $12.65 Mil.

Jacobio Pharmaceuticals Group Co's quarterly Long-Term Debt increased from Dec. 2024 ($2.20 Mil) to Jun. 2025 ($7.25 Mil) and increased from Jun. 2025 ($7.25 Mil) to Dec. 2025 ($12.65 Mil).

Jacobio Pharmaceuticals Group Co's annual Long-Term Debt increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($2.20 Mil) and increased from Dec. 2024 ($2.20 Mil) to Dec. 2025 ($12.65 Mil).

Jacobio Pharmaceuticals Group Co  (OTCPK:JBPHF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Jacobio Pharmaceuticals Group Co Long-Term Debt Related Terms

Jacobio Pharmaceuticals Group Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Jacobio Pharmaceuticals Group Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jacobio Pharmaceuticals Group Co Long-Term Debt Chart

Jacobio Pharmaceuticals Group Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 2.20 12.65

Jacobio Pharmaceuticals Group Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 2.20 7.25 12.65
JBPHF
54GF Score
Jacobio Pharmaceuticals Group Co Ltd JBPHF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $12.65 Mil mean?
Jacobio Pharmaceuticals Group Co (JBPHF) has a Long-Term Debt of $12.65 Mil as of Dec. 2025.
Is Jacobio Pharmaceuticals Group Co's Long-Term Debt too high?
Jacobio Pharmaceuticals Group Co's current Long-Term Debt is $12.65 Mil. Overall, Jacobio Pharmaceuticals Group Co has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Jacobio Pharmaceuticals Group Co's Long-Term Debt compare to VRTX and REGN?
Jacobio Pharmaceuticals Group Co's Long-Term Debt of $12.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Jacobio Pharmaceuticals Group Co's current Long-Term Debt is $12.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jacobio Pharmaceuticals Group Co stock overvalued right now?
Jacobio Pharmaceuticals Group Co (JBPHF) has a current Long-Term Debt of $12.65 Mil. The stock's GF Value™ is $0.34, compared to a current price of $0.87 — trading 155.2% above its estimated fair value. The current Long-Term Debt is $12.65 Mil. Jacobio Pharmaceuticals Group Co's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Jacobio Pharmaceuticals Group Co (JBPHF), the current Long-Term Debt is $12.65 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jacobio Pharmaceuticals Group Co (JBPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Jacobio Pharmaceuticals Group Co stock appears to be overvalued. The current stock price of $0.87 is trading 155.2% above its estimated GF Value™ of $0.34.

Key valuation signals for JBPHF:

  • Long-Term Debt: $12.65 Mil
  • GF Value™: $0.34 vs. price of $0.87 (155.2% above fair value)
  • GF Score™: 54/100 with 6 warning signs

No single metric tells the full story. See the JBPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jacobio Pharmaceuticals Group Co Business Description

Other Exchanges 01167:Hong Kong77V:Germany
Address No.105 Jinghai 3rd Road, Building 8, Beijing Economic-Technological Development Area, Beijing, CHN
Jacobio Pharmaceuticals Group Co Ltd is a clinical-stage pharmaceutical company focusing on the in-house discovery and development of oncology therapies. The company is engaged in developing breakthrough cancer therapies for patients. The producst pipeline of the company includes KRAS G12C inhibitor, SHP2 inhibitor, Pan-KRAS inhibitor, KRAS G12D ADC JAB-BX600, Aurora Kinase A (AURKA) inhibitor, BET inhibitor, P53 Y220C mutant proteins, and others.
54GF Score

Get the complete analysis for JBPHF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.87
Price
$0.34
GF Value